Oral versus intramuscular progesterone for in vitro fertilization: a prospective randomized study

Objective: To evaluate the efficacy of oral micronized progesterone compare d with IM progesterone in oil for luteal support in patients undergoing IVF who are treated with a GnRH agonist. Design: Randomized prospective clinical trial. Setting: University-based IVF center. Patient(s): Women <40 years of age who were undergoing TVF with luteal GnRH pituitary down-regulation. Intervention(s): Patients were randomized to receive either oral micronized progesterone (200 mg three times daily) or IM progesterone (50 mg daily). Main Outcome Measure(s): Progesterone levels at standardized days 21 and 28 , and pregnancy and embryo implantation rates. Result(s): Day 21 progesterone levels were 77.6 +/- 13.2 ng/mL in the IM gr oup and 81.5 +/- 16.2 ng/mL in the Oral group. Day 28 progesterone levels w ere 76.3 +/- 15.0 ng/mL in the IM group and 53.6 +/- 10.1 ng/mL in the oral group. The clinical pregnancy rates were 57.9% and 45.8% for the IM and or al groups, respectively. The implantation rate per embryo was significantly higher in the IM group (40.9%) than in the oral group Conclusion(s): When used according to our protocols, oral progesterone and IM progesterone result in comparable levels of circulating progesterone. Ho wever, oral progesterone results in a reduced implantation rate per embryo. (Fertil Steril(R) 1999;71:614-8. (C)1999 by American Society for Reproduct ive Medicine.).